{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:55:04Z","timestamp":1790182504591,"version":"4.1.0"},"reference-count":36,"publisher":"Aging and Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2021]]},"DOI":"10.14336\/ad.2021.0311","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T13:41:37Z","timestamp":1625319697000},"page":"1000","source":"Crossref","is-referenced-by-count":97,"title":["Acute Stroke Management: Overview and Recent Updates"],"prefix":"10.14336","volume":"12","author":[{"given":"Mary","family":"Hollist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainier","family":"Cabatbat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaida F","family":"Kirmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool F","family":"Kirmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2021.0311-1","doi-asserted-by":"crossref","unstructured":"Engelhardt E (2017). Apoplexy, cerebrovascular disease, and stroke: Historical evolution of terms and definitions. Dement Neuropsychol, 11:449-453.","DOI":"10.1590\/1980-57642016dn11-040016"},{"key":"key-10.14336\/AD.2021.0311-2","doi-asserted-by":"crossref","unstructured":"Furie K (2020). Epidemiology and Primary Prevention of Stroke. Continuum (Minneap Minn), 26:260-267.","DOI":"10.1212\/CON.0000000000000831"},{"key":"key-10.14336\/AD.2021.0311-3","doi-asserted-by":"crossref","unstructured":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 333:1581-7.","DOI":"10.1056\/NEJM199512143332401"},{"key":"key-10.14336\/AD.2021.0311-4","doi-asserted-by":"crossref","unstructured":"Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al (1998). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet, 352:1245-51.","DOI":"10.1016\/S0140-6736(98)08020-9"},{"key":"key-10.14336\/AD.2021.0311-5","doi-asserted-by":"crossref","unstructured":"Alper BS, Foster G, Thabane L, Rae-Grant A, Malone-Moses M, Manheimer E (2020). Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. BMJ Evid Based Med, 25:168-171.","DOI":"10.1136\/bmjebm-2020-111386"},{"key":"key-10.14336\/AD.2021.0311-6","unstructured":"Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al (2018). WAKE-UP Investigators. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med, 379:611-622."},{"key":"key-10.14336\/AD.2021.0311-7","doi-asserted-by":"crossref","unstructured":"Schwamm LH, Wu O, Song SS, Latour LL, Ford AL, Hsia AW, et al (2018). MR WITNESS Investigators. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. Ann Neurol, 83:980-993.","DOI":"10.1002\/ana.25235"},{"key":"key-10.14336\/AD.2021.0311-8","doi-asserted-by":"crossref","unstructured":"Amiri H, Bluhmki E, Bendszus M, Eschenfelder CC, Donnan GA, Leys D, et al (2016). European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND. Int J Stroke, 11:260-7.","DOI":"10.1177\/1747493015620805"},{"key":"key-10.14336\/AD.2021.0311-9","doi-asserted-by":"crossref","unstructured":"Bevers MB, Battey TWK, Ostwaldt AC, Jahan R, Saver JL, Kimberly WT, Kidwell CS (2018). Apparent Diffusion Coefficient Signal Intensity Ratio Predicts the Effect of Revascularization on Ischemic Cerebral Edema. Cerebrovasc Dis, 45:93-100.","DOI":"10.1159\/000487406"},{"key":"key-10.14336\/AD.2021.0311-10","doi-asserted-by":"crossref","unstructured":"Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al (1994). A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A, 91:3670-4.","DOI":"10.1073\/pnas.91.9.3670"},{"key":"key-10.14336\/AD.2021.0311-11","doi-asserted-by":"crossref","unstructured":"Huang X, Moreton FC, Kalladka D, Cheripelli BK, MacIsaac R, Tait RC, Muir KW (2015). Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. Stroke, 46:3543-6.","DOI":"10.1161\/STROKEAHA.115.011290"},{"key":"key-10.14336\/AD.2021.0311-12","doi-asserted-by":"crossref","unstructured":"R\u00f8nning OM, Logallo N, Thommessen B, Tobro H, Novotny V, Kvistad CE, et al (2019). Tenecteplase Vs Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. Stroke, 50:498-500.","DOI":"10.1161\/STROKEAHA.118.024223"},{"key":"key-10.14336\/AD.2021.0311-13","doi-asserted-by":"crossref","unstructured":"Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al (2012). A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med, 366:1099-107.","DOI":"10.1056\/NEJMoa1109842"},{"key":"key-10.14336\/AD.2021.0311-14","doi-asserted-by":"crossref","unstructured":"Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, R\u00f8nning OM, Thommessen B, et al (2017). Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol, 16:781-788.","DOI":"10.1016\/S1474-4422(17)30253-3"},{"key":"key-10.14336\/AD.2021.0311-15","doi-asserted-by":"crossref","unstructured":"Ringleb P, Bendszus M, Bluhmki E, et al (2019). Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. Int J Stroke, 14:483-490.","DOI":"10.1177\/1747493019840938"},{"key":"key-10.14336\/AD.2021.0311-16","unstructured":"Ma H, Campbell BCV, Parsons MW, et al (2019). Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med, 380:1795-1803."},{"key":"key-10.14336\/AD.2021.0311-17","doi-asserted-by":"crossref","unstructured":"Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J,et al (2018). PRISMS Investigators. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurological Deficits: The PRISMS Randomized Clinical Trial. JAMA, 320:156-166.","DOI":"10.1001\/jama.2018.8496"},{"key":"key-10.14336\/AD.2021.0311-18","unstructured":"Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al (2018). EXTEND-IA TNK Investigators. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med, 378:1573-1582."},{"key":"key-10.14336\/AD.2021.0311-19","doi-asserted-by":"crossref","unstructured":"Fiorella D, Hirsch JA, Woo HH, Rasmussen PA, Shazam Hussain M, Hui FK, et al (2012). Should neurointerventional fellowship training be suspended indefinitely? J Neurointerv Surg, 4:315-8.","DOI":"10.1136\/neurintsurg-2012-010471"},{"key":"key-10.14336\/AD.2021.0311-20","unstructured":"Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al (2015). MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med, 372:11-20."},{"key":"key-10.14336\/AD.2021.0311-21","doi-asserted-by":"crossref","unstructured":"Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al (2016). HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet, 387:1723-31.","DOI":"10.1016\/S0140-6736(16)00163-X"},{"key":"key-10.14336\/AD.2021.0311-22","unstructured":"Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al (2018). DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med, 378:11-21."},{"key":"key-10.14336\/AD.2021.0311-23","doi-asserted-by":"crossref","unstructured":"Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al (2018). DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med, 378:708-718.","DOI":"10.1056\/NEJMoa1713973"},{"key":"key-10.14336\/AD.2021.0311-24","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al (2013). CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med, 369:11-9.","DOI":"10.1056\/NEJMoa1215340"},{"key":"key-10.14336\/AD.2021.0311-25","doi-asserted-by":"crossref","unstructured":"Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al (2018). Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med, 379:215-225.","DOI":"10.1056\/NEJMoa1800410"},{"key":"key-10.14336\/AD.2021.0311-26","doi-asserted-by":"crossref","unstructured":"Kaushik A, Deora S, Choudhary R (2020). Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med, 383:1692-1693.","DOI":"10.1056\/NEJMc2027491"},{"key":"key-10.14336\/AD.2021.0311-27","unstructured":"Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al (2019). EXTEND Investigators. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med, 380:1795-1803."},{"key":"key-10.14336\/AD.2021.0311-28","doi-asserted-by":"crossref","unstructured":"Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, et al (2019). WAKE-UP Investigators. Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial. JAMA Neurol, 76:641-649.","DOI":"10.1001\/jamaneurol.2019.0351"},{"key":"key-10.14336\/AD.2021.0311-29","doi-asserted-by":"crossref","unstructured":"Hacke W, Kaste M, Bluhmki E, Brozman M, D\u00e1valos A, Guidetti D, et al (2008). ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med, 359:1317-29.","DOI":"10.1056\/NEJMoa0804656"},{"key":"key-10.14336\/AD.2021.0311-30","unstructured":"Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al (2008). EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol, 7:299-309."},{"key":"key-10.14336\/AD.2021.0311-31","doi-asserted-by":"crossref","unstructured":"Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al (2016). THERAPY Trial Investigators*. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. Stroke, 47:2331-8.","DOI":"10.1161\/STROKEAHA.116.013372"},{"key":"key-10.14336\/AD.2021.0311-32","unstructured":"Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al (2015). REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med, 372:2296-306."},{"key":"key-10.14336\/AD.2021.0311-33","doi-asserted-by":"crossref","unstructured":"Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al (2015). SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med, 372:2285-95.","DOI":"10.1056\/NEJMoa1415061"},{"key":"key-10.14336\/AD.2021.0311-34","unstructured":"Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al (2015). ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med, 372:1019-30."},{"key":"key-10.14336\/AD.2021.0311-35","unstructured":"Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al (2015). EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med, 372:1009-18."},{"key":"key-10.14336\/AD.2021.0311-36","doi-asserted-by":"crossref","unstructured":"Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al (2020). THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med, 383:207-217.","DOI":"10.1056\/NEJMoa1916870"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aginganddisease.org\/fileup\/2152-5250\/PDF\/ad-0-0-0-2103221947-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T21:27:49Z","timestamp":1627507669000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2021.0311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2021.0311","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}